Real-World Outcomes and Experiences With Mavacamten Treatment for Adults with Obstructive Hypertrophic Cardiomyopathy in the US

What this Trial Is About

This research aims to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy oHCM who are treated with mavacamten. It also explores the experiences of both patients and physicians using mavacamten in community-based practices across the US. The study is observational and focuses on gathering comprehensive data from actual clinical settings. Participants with obstructive HCM who have been prescribed mavacamten will be included. The study involves retrospective chart reviews of patients treated with mavacamten from April 2022 to December 2024, and a patient survey requiring English proficiency and access to a computer or smartphone. Physicians treating these patients will also provide feedback about treatment preferences and implementation. The treatment follows the product label for mavacamten use. Participants will have their medical records reviewed for various baseline and follow-up clinical data, including blood pressure, diagnosis date, genetic testing, family history, comorbidities, prior surgeries, and heart function class. Data on mavacamten treatment duration, dose changes, reasons for dose adjustments or discontinuation, and heart function recovery are collected at baseline and at weeks 4, 8, 12, and 24. Structured interviews with physicians gather perspectives on treatment eligibility and experience. The study duration and assessments occur up to 24 weeks from baseline.

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US